Experimental obesity drug retatrutide halved knee arthritis pain in two-thirds of patients in two large trials
- In two phase 3 trials with more than 1,000 patients, the experimental drug retatrutide cut knee osteoarthritis pain by at least half in about two-thirds of people, versus 38% on placebo.
- Those on the highest dose lost about a quarter of their body weight on average.
- The drug is not yet approved, and it is unknown whether it slows joint damage or reduces the need for knee replacement.
Two phase 3 trials led by Northwestern University and published in the New England Journal of Medicine on November 8, 2026 show that Eli Lilly's experimental obesity drug retatrutide substantially eased knee osteoarthritis pain in people with obesity or overweight.
What the trials found
TRIUMPH-4 and TRIUMPH-1-OA enrolled 1,019 adults without diabetes who had chronic knee pain and X-ray-confirmed osteoarthritis. They received a weekly injection of retatrutide or placebo for 68 and 80 weeks. According to Northwestern:
Also read: MHRA seizes £2 million of fake retatrutide and tirzepatide weight-loss pens in Birmingham
- About two-thirds of people on retatrutide had at least a 50% reduction in knee pain, compared with 38% on placebo.
- At the highest dose (12 mg), participants lost about a quarter of their body weight on average (23.7% and 24.8% in the two trials), versus roughly 4% to 5% on placebo.
- Blood pressure, blood lipids and markers of inflammation also improved.
Retatrutide acts on receptors for three natural hormones, whereas semaglutide and tirzepatide act on one or two.
Side effects and limits
Gastrointestinal problems were common. About 15% to 18% of people on the top dose stopped treatment because of side effects, compared with 4% to 6% on placebo, and some reported abnormal skin sensations (dysesthesia). Retatrutide remains experimental and is not approved, and both trials were funded by the manufacturer.
Lead researcher Thomas Schnitzer says the key open question is whether the drug slows joint damage enough to reduce the need for knee replacement surgery; patients who already needed a replacement were excluded. Weight loss remains one of the most effective ways to take load off painful knees, whether through medication or, for suitable candidates, gastric sleeve surgery.
Sources: Northwestern University (EurekAlert!), New England Journal of Medicine, News-Medical
This story is relayed from the source named above; responsibility for its content rests with the original source.
FAQ
What is retatrutide?
Retatrutide is an experimental once-weekly obesity injection from Eli Lilly that acts on receptors for three natural hormones; it is not yet approved.
Does retatrutide reduce knee osteoarthritis pain?
In two phase 3 trials, retatrutide cut knee osteoarthritis pain by at least 50% in about two-thirds of patients, versus 38% on placebo.
How much weight do people lose on retatrutide?
In the knee osteoarthritis trials, people on the highest dose of retatrutide lost about a quarter of their body weight on average.
Can retatrutide replace knee replacement surgery?
It is not yet known whether retatrutide slows knee joint damage or reduces the need for knee replacement; the trials were not designed to answer that.



